Heart failure patients discharged from the hospital with a reduced level of a common hormone produced by the heart had significantly lower rates of readmission and lower death rates, according to a new study conducted by researchers at the Intermountain Medical Centre Heart Institute in Salt Lake City.
Researchers found that patients who attained a reduction level of a hormone called B-type natriuretic peptide, or BNP, over their heart failure hospitalisation had a 30 per cent lower rate of readmission to the hospital within 30 days of their original discharge compared to those without a reduction. They also had a significant 54 per cent lower mortality rate within 30 days.
For the study, Intermountain Medical Centre Heart Institute researchers analysed 6,887 patients with a primary diagnosis of heart failure who were discharged from any of Intermountain Healthcare’s 22 hospitals between January 2014 and May 2017.
Overall, those patients had a 30-day readmission rate of 21.1 per cent and a 30-day mortality rate of 12.8 per cent. But patients with reduced levels of BNP had a readmission rate of just 16.1 per cent and a mortality rate of 7.1 per cent after 30 days.
Findings from the Intermountain Medical Centre Heart Institute study were presented at the 2017 Scientific Sessions of the American Heart Association, in Anaheim, CA.
‘Previously there wasn’t enough data in the medical literature that examined the benefit of conducting serial measurements of BNP and the relationship between reduced
BNP rates and better outcomes,’ said Jose Benuzillo, MS, an Outcomes Analyst for Intermountain Healthcare’s Cardiovascular Clinical Programme, who led the study.
The reduction in BNP among Intermountain Healthcare’s heart failure patients was determined by calculating the relative difference in BNP levels between the admission BNP and the discharge BNP during their hospital stay. About 19 per cent of the patients in the study (1,315) had serial measurements.
‘Further research is needed to understand which interventions caused the drop in levels of BNP, and which patients responded,’ Benuzillo said.
‘We also hope to determine the threshold level of BNP at which better readmission and mortality outcomes are achieved.’
How will patients benefit?
‘Relative changes in BNP may help physicians determine which patients could benefit from advanced medical therapies or screening for end-of-life care,’ Benuzillo said.
